Author:
André Fabrice,Hee Park Yeon,Kim Sung-Bae,Takano Toshimi,Im Seock-Ah,Borges Giuliano,Lima Joao Paulo,Aksoy Sercan,Gavila Gregori Joaquin,De Laurentiis Michelino,Bianchini Giampaolo,Roylance Rebecca,Miyoshi Yasuo,Armstrong Anne,Sinha Rajni,Ruiz Borrego Manuel,Lim Elgene,Ettl Johannes,Yerushalmi Rinat,Zagouri Flora,Duhoux Francois P,Fehm Tanja,Gambhire Dhiraj,Cathcart Jillian,Wu Cai,Chu Changan,Egorov Anton,Krop Ian
Reference26 articles.
1. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort;Grinda;ESMO Open,2021
2. Drug-resistant HER2-positive breast cancer: molecular mechanisms and overcoming strategies;Wu;Front Pharmacol,2022
3. Breast cancer;Harbeck;Nat Rev Dis Primers,2019
4. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE);Bachelot;Ann Oncol,2019
5. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2020
Cited by
124 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献